TF-1

Medicenna Presents Preclinical Data Demonstrating Anti-Tumor Activity of its Anti-PD1-IL-2 BiSKIT and Long-Acting IL-4/IL-13 Super-antagonist at Cytokines 2022

Retrieved on: 
Thursday, September 22, 2022
Half-life, P69, Biskit, Type, CD25, FDA, Bifunctional, Cancer, Company, Macrophage, Neoplasm, GBM, CD122, Melanoma, News, Cytokine, Forward-looking statement, Program, Type 2, Tams, NK, Colon, International Cytokine & Interferon Society, Breast cancer, Growth, CEO, TF-1, Serum, Doctor of Philosophy, TME, MDNA, NASDAQ, Immunotherapy, MDSC, GLOBE, Skin, Brain, EMA, Vaccine, Pharmaceutical industry, Online shopping, FC

TORONTO and HOUSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced presentation of data from two preclinical programs that demonstrate the anti-tumor activity of the Company’s anti-PD1-IL-2 (aka MDNA223) BiSKIT (Bi-functional SuperKines for ImmunoTherapy) and long-acting IL-4/IL-13 super-antagonist (aka MDNA413). The data are featured in two separate poster presentations at the 10th Annual Meeting of the International Cytokine & Interferon Society (Cytokines 2022), which is taking place both virtually and in-person at the Hilton Waikoloa Village, in Big Island, Hawaii.

Key Points: 
  • In addition, data on our long-acting MDNA413 Superkine demonstrated its potential to reverse the immunosuppressive tumor microenvironment that are known to limit the efficacy of cancer immunotherapies.
  • Poster P110 includes preclinical data from in vitro and in vivo studies of MDNA223, a next generation BiSKIT consisting of an anti-PD1 antibody linked to an IL-2 super-agonist (MDNA109FEAA).
  • In vivo murine data showed MDNA223 exhibiting a prolonged pharmacodynamic response extending beyond the duration of pharmacokinetic exposure.
  • Poster P69 includes preclinical data from in vitro and in vivo studies of Fc-MDNA413, a novel, long-acting IL-4/IL-13 Superkine.

Medicenna Presents Preclinical Data Demonstrating Anti-Cancer Activity of a Long-Acting IL-13 Super-Antagonist at the AACR Annual Meeting

Retrieved on: 
Friday, April 8, 2022
Company, Abstract, FC, TF-1, NASDAQ, Forward-looking statement, TME, Interferon type II, GBM, Neoplasm, AACR, Half-life, Metastasis, Myelocyte, American Association, CEO, CD25, CD122, Brain, American Association for Cancer Research, Association, Tams, Annual general meeting, MDSC, MDNA, GLOBE, Type, IL13, EMA, Macrophage, News, Bifunctional, NK, FDA, Pharmaceutical industry, Vaccine

TORONTO and HOUSTON, April 08, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced new preclinical data on its long-acting IL-13 super-antagonist, Fc-MDNA413, in an electronic poster at the American Association for Cancer Research (AACR) Annual Meeting. Fc-MDNA413 is derived from Medicenna’s Superkine platform and comprises of an IL-13 super-antagonist (MDNA413) fused to the Fc domain for half-life extension.

Key Points: 
  • Fc-MDNA413 is derived from Medicennas Superkine platform and comprises of an IL-13 super-antagonist (MDNA413) fused to the Fc domain for half-life extension.
  • Included in the AACR poster are data from in vitro and murine studies evaluating the affinity profile, target selectivity and anti-cancer activity of Fc-MDNA413 in a poorly immunogenic (cold) tumor model.
  • These data demonstrate for the first time that an IL-13 Superkine, such as MDNA413, can block the pathways utilized by TAMs and MDSCs to promote cancer growth.
  • A copy will also be posted to the Events andPresentations page of Medicennas website following the conclusion of the meeting.